Nuformix PLC Results Pre-clinical Pilot Study in IPF for NXP004 (6183W)
19 August 2020 - 11:24PM
UK Regulatory
TIDMNFX
RNS Number : 6183W
Nuformix PLC
19 August 2020
Nuformix plc
Nuformix Reports Results from Pre-clinical Pilot Study in IPF
for NXP004 Programme
Cambridge, UK - 19 August 2020: Nuformix plc (LSE:NFX)
("Nuformix" or "the Group"), a pharmaceutical development company
focused on unlocking the therapeutic potential and value of known
drugs to develop new novel medicines to provide enhanced benefit,
announces results from the pre-clinical pilot study and evaluation
of its NXP004 fibrosis programme in human idiopathic pulmonary
fibrosis (IPF), against standard of care.
As a response to COVID-19, staff and equipment at our research
partner, Newcastle Fibrosis Research Group (NFRG) had been
commandeered on Government orders to support national testing
efforts at Milton Keynes and completion of this pre-clinical pilot
study had therefore been delayed.
IPF is characterised by excessive deposition and remodelling of
extracellular matrix (ECM), leading to lung scarring and loss of
respiratory function. Over-production of key ECM components are a
key driver in IPF progression:
-- NXP004 showed a dose-dependent reduction in the secretion of several key ECM components
-- These data suggest NXP004 compares favourably to current
standard of care with regard to anti-fibrotic activity in this
model
-- Delivery of a full pre-clinical study data set in multiple
human IPF tissue samples is the next focus
Dr Joanne Holland, Chief Scientific Officer, said:
" Whilst this is only the pilot phase of this pre-clinical
study, positive indications of anti-fibrotic activity are very
encouraging. We would like to thank our research partner NFRG for
prioritising completion of this study under challenging
circumstances."
Enquiries:
Nuformix plc
Dr Joanne Holland, CSO
Fleur Wood, Investor Relations
Email: fleur.wood@nuformix.com +44 (0)1223 627222
Novum Securities Limited
Jon Belliss / Colin Rowbury +44 (0)20 7399 9427
About NXP004 - Fibrosis programme in human IPF
Nuformix has completed a pre-clinical pilot study to investigate
the potential for NXP004 as a treatment for IPF in human IPF lung
tissue with its research partner, Newcastle Fibrosis Research Group
(NFRG). The marketed form of this drug is very successful in its
current indication, its formulation and side-effects have posed a
significant challenge to extending the use of the drug into new
indications that could also benefit from its mechanism of action.
The Company's instinct was to use cocrystal technology to overcome
some of the formulation issues and open up potential new
therapeutic applications. Evaluation of the full pre-clinical data
alongside exploring new formulation options with our cocrystal
forms will enable us to begin to explore additional business
development options.
About Cocrystals
Pharmaceutical cocrystals are materials composed of two or more
different molecules, usually an active pharmaceutical ingredient
together with a pharmaceutically acceptable "coformer" molecule.
Cocrystals can be engineered to enhance the bioavailability,
pharmacokinetics, stability and manufacturing of drug products.
About Idiopathic Pulmonary Fibrosis
IPF is a rare, debilitating, and fatal lung disease that causes
progressive lung scarring. With a global prevalence of 13-20 per
100,000 people worldwide the expected survival rate of patients is
only 3-5 years with lung transplantation the only survival option.
The growing global IPF market is expected to reach $5.9 billion by
2025 (CAGR 13.1%) (iHealthcareAnalyst, Inc 2019)
About Nuformix
Nuformix is a pharmaceutical development company focused on
unlocking the therapeutic potential and value of known drugs to
develop new novel medicines which provide therapeutic and
commercial advantages to the currently available drug form.
Nuformix's model of repurposing drugs utilises many technologies
but is focussed on its acknowledged expertise in the use of
cocrystal technology through which the Group has developed and
patented novel forms of small molecules. Its platform is not
therapy-specific but instead has broad application across a wide
range of indications. Using its technology, the Group is developing
proprietary medicines for its own development pipeline and in
partnership with pharmaceutical and biotech companies.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX. For more information please
visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESKKCBBNBKDBFD
(END) Dow Jones Newswires
August 19, 2020 09:24 ET (13:24 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024